Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

Kaira, Kyoichi; Higuchi, Tetsuya; Naruse, Ichiro; Arisaka, Yukiko; Tokue, Azusa; Altan, Bolag; Suda, Satoshi; Mogi, Akira; Shimizu, Kimihiro; Sunaga, Noriaki; Hisada, Takeshi; Kitano, Shigehisa; Obinata, Hideru; Yokobori, Takehiko; Mori, Keita; Nishiyama, Masahiko; Tsushima, Yoshihito; Asao, Takayuki

doi:10.1007/s00259-017-3806-1

Cited by 170 publications

(128 citation statements)

References 26 publications

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…These criteria were also the first to introduce the concept of SULpeak within the area of highest uptake in the tumour, which can be measured within a spherical region of interest of diameter 1.2 cm (1 cm 3 volume). The use of PERCIST criteria with respect to response to immunotherapy has been described only rather recently [22]. …”

Section: Review Of the Use Of Fdg Pet In Immunotherapy Response Assesmentioning

confidence: 99%

“…In a recent study assessing response of NSCLC to immunotherapy [22], 24 patients treated with nivolumab were investigated at baseline and 1 month after the start of treatment. Response was determined using either morphological (RECIST 1.1) or PERCIST criteria, along with SUVmax, metabolic tumour volume (MTV) and total lesion glycolysis (TLG).…”

Section: Review Of the Use Of Fdg Pet In Immunotherapy Response Assesmentioning

confidence: 99%

See 1 more Smart Citation

FDG PET/CT for assessing tumour response to immunotherapy

Aide

Hicks

Tourneau

et al. 2018

Eur J Nucl Med Mol Imaging

214

View full text Add to dashboard Cite

This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts’ experience. Representative clinical cases are also discussed.

show abstract

Section: Review Of the Use Of Fdg Pet In Immunotherapy Response Assesmentioning

confidence: 99%

Section: Review Of the Use Of Fdg Pet In Immunotherapy Response Assesmentioning

confidence: 99%

FDG PET/CT for assessing tumour response to immunotherapy

Aide

Hicks

Tourneau

et al. 2018

Eur J Nucl Med Mol Imaging

214

View full text Add to dashboard Cite

show abstract

“…The positive correlation between CD147 expression and PD‐L1 expression in both EGFR‐TKI‐sensitive and EGFR‐TKI‐resistant NSCLC cell lines suggested that PD‐L1 expression could be increased by the CD147‐mediated promotion of glucose metabolic reprogramming via EGFR signaling conferred by EGFR‐activating mutations. Intriguingly, a preliminary study indicated that the metabolic response detected by 18 F‐FDG PET/CT was predictive of early response and survival at 1 month after anti‐PD1 treatment (nivolumab) in previously treated NSCLC …”

Section: Discussionmentioning

confidence: 99%

CD147‐mediated glucose metabolic regulation contributes to the predictive role of ¹⁸F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC

Fu²,

Zhu³

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

The aim of this study is to investigate the role of CD147 in glucose metabolic regulation and its association with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment sensitivity prediction using 18F‐fluorodeoxyglucose (18F‐FDG) PET/CT imaging in non‐small cell lung cancer (NSCLC). In this study, four human NSCLC cell lines with different EGFR‐TKI responses were used to detect p‐EGFR/EGFR and CD147 expression via Western blotting and flow cytometric analyses. Radioactive uptake of 18F‐FDG by established stable NSCLC cell lines (HCC827, H1975) with different levels of CD147 expression and the corresponding xenografts was assessed through γ‐radioimmunoassays in vitro and micro‐PET/CT imaging in vivo to study the role of CD147 in glucose metabolic reprogramming. Correlation analyses were performed to investigate the association between CD147 expression and PD‐L1 expression in stable NSCLC cell lines. Higher CD147 expression was found in EGFR‐TKI‐sensitive NSCLC cell lines than in relatively resistant NSCLC cell lines (HCC827>PC9>A549>H1975). CD147 could promote 18F‐FDG uptake by HCC827 and H1975 cells in vitro and in vivo through an EGFR‐initiated Akt/mTOR‐dependent signaling pathway. Programmed cell death‐ligand 1 (PD‐L1) expression was positively correlated with CD147 expression in human NSCLC cell lines. EGFR‐TKI treatment sensitivity prediction in NSCLC using 18F‐FDG PET/CT imaging significantly correlated with CD147‐mediated glucose metabolic regulation via the Akt/mTOR‐dependent pathway. Moreover, PD‐L1 expression in NSCLC cell lines could be regulated by CD147, suggesting a potential immunosuppression induced by the upregulation of tumor glucose metabolism.

show abstract

“…Their findings suggested the occurrence of early inflammatory response at the tumor milieu was induced by ICB. Results from another trial involving 24 NSCLC patients receiving nivolumab showed that metabolic response evaluated by 18 F‐FDG could accurately predict response and prognosis at 1 month after nivolumab therapy . Ito and colleagues found that tumor response on 18 F‐FDG PET/CT scans according to PET response criteria in solid tumors (PERCIST) was significantly associated with OS in melanoma patients undergoing ipilimumab therapy .…”

Section: Imaging Biomarkers For Immune Checkpoint Therapymentioning

confidence: 99%

“…Results from another trial involving 24 NSCLC patients receiving nivolumab showed that metabolic response evaluated by 18 F-FDG could accurately predict response and prognosis at 1 month after nivolumab therapy. 58 Ito and colleagues found that tumor response on 18 F-FDG PET/CT scans according to PET response criteria in solid tumors (PERCIST) was significantly associated with OS in melanoma patients undergoing ipilimumab therapy. 60 Meanwhile, in another study, they also revealed that tumor burden measured with whole-body metabolic tumor volume (wMTV) can serve as a robust biomarker for predicting prognosis in melanoma patients treated with ipilimumab.…”

Section: Anatomic Imagingmentioning

confidence: 99%

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

2019

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) represents a promising approach in cancer therapy. Owing to the peculiar biologic mechanisms of anticancer activity, checkpoint blockers are accompanied with distinctive response patterns and toxicity profiles. Medical imaging is the cornerstone for response assessment to immunotherapy and plays a critical role in monitoring of immune‐related adverse events (irAEs). Imaging‐based biomarkers have shown tremendous potential for the prediction of therapeutic efficacies and clinical outcomes in patients treated with checkpoint inhibitors. In this article, the landscape of current response assessment systems for immunotherapy was reviewed with a special focus on the latest advances in the assessment of responses to ICB. Emerging imaging biomarkers were discussed along with the challenges regarding their clinical transformation. In addition, the biological mechanisms and clinical applications of ICB and irAEs were also within the scope of this review.

show abstract

Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

Abstract: Metabolic response by F-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment.

Cited by 170 publications

References 26 publications

FDG PET/CT for assessing tumour response to immunotherapy

FDG PET/CT for assessing tumour response to immunotherapy

CD147‐mediated glucose metabolic regulation contributes to the predictive role of ¹⁸F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

Contact Info

Product

Resources

About

Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

Abstract: Metabolic response by F-FDG was effective in predicting efficacy and survival at 1 month after nivolumab treatment.

Cited by 170 publications

References 26 publications

FDG PET/CT for assessing tumour response to immunotherapy

FDG PET/CT for assessing tumour response to immunotherapy

CD147‐mediated glucose metabolic regulation contributes to the predictive role of 18F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC

Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction

Contact Info

Product

Resources

About

CD147‐mediated glucose metabolic regulation contributes to the predictive role of ¹⁸F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC